Study on Short Course Radiotherapy for Treating Glioblastoma: SAGA Study

Program Overview

This study is testing whether a shorter course of radiotherapy can be as effective as the standard treatment for glioblastoma, a type of brain cancer. Radiotherapy uses high-energy rays to kill cancer cells. The shorter course delivers higher doses over a shorter time, which might kill more cancer cells and cause fewer side effects.

Description

The main goal of this study is to see if patients with glioblastoma who receive a shorter, more intense course of radiotherapy live as long as those who receive the standard treatment. Researchers also want to check if the shorter treatment is safe and how it affects patients' quality of life.

Patients will be randomly assigned to one of two groups:

• Group A: Will receive short course radiotherapy over 1-2 weeks, along with the drug temozolomide taken by mouth during and after radiation.
• Group B: Will receive standard course radiotherapy over 3-6 weeks, with temozolomide taken daily during and after radiation.

All patients will have PET/CT and MRI scans to monitor the cancer. Blood samples may also be collected.

After treatment, patients will have follow-up visits every 2 months for the first year, every 3 months for the second year, and every 4 months for the third year. After 3 years, they will be checked at least once a year until 5 years after treatment.

Eligibility Criteria